Investigational drug · Phase 3
LW402
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Moderate to Severe Atopic Dermatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "LW402"
First trial start
2026
Mar 3, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LW402", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "LW402" as an intervention, largest first.
- Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
NCT07370909 · 480 participants (planned) · Start Mar 3, 2026 · Primary completion Mar 31, 2028
Drug: LW402; Placebo · For: Moderate to Severe Atopic Dermatitis
Sites: Beijing, China
- Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental VitiligoPivotal-lookingNot yet recruiting
Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
NCT07556471 · 180 participants (planned) · Start May 31, 2026 · Primary completion Feb 1, 2028
Drug: Experimental LW402 Tablet; Placebo · For: Non-Segmental Vitiligo (NSV)
- Study of LW402 in Moderate-to-Severe Atopic DermatitisPivotal-lookingCompleted
Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
NCT07186387 · 144 participants · Start May 11, 2023 · Primary completion Sep 25, 2024
Drug: LW402; LW402 placebo · For: Atopic Dermatitis (AD)
Sites: Beijing, China
Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
NCT06800157 · 72 participants · Start Feb 27, 2023 · Primary completion May 26, 2024
Drug: Drug: LW402; Other: placebo and 1 more · For: Arthritis, Rheumatoid
Sites: Beijing, China
Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
NCT07546149 · 36 participants · Start Oct 15, 2025 · Primary completion Dec 9, 2025
Drug: Experimental; Placebo · For: Safety Evaluation of Escalating Doses
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of LW402, a preferential Janus kinase 1 inhibitor in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial.
Gui Y, Jiang F, Xin L, et al. · Front Pharmacol 2026
- Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis.
Zhang N, Zhang C, Zeng Z, et al. · J Inflamm Res 2021
Also in development for Moderate to Severe Atopic Dermatitis
- SHR-1819Phase 38 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Seasonal Allergic Rhinitis, Moderate to Severe Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
- RezpegaldesleukinNKTR-358, REZPEGPhase 34 trials
Nektar Therapeutics · Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata
- CMS-D001Phase 32 trials
Dermavon Holdings Limited · Moderate to Severe Plaque Psoriasis, Moderate to Severe Atopic Dermatitis
- VC005 groupPhase 32 trials
Jiangsu vcare pharmaceutical technology co., LTD · Atopic Dermatitis, Moderate to Severe Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.